Displaying 173 (all) recruiting clinical trials.
-
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations
This is a phase 2 study testing how well the study medicines vismodegib (a Hedgehog pathway inhibitor), GSK2256098 (a selective focal adhesion kinase (FAK) inhibitor ...
Phase
Interventional
-
PNOC029: Nivolumab and DAY101 for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults
This study is designed for patients who have craniopharyngioma (a rare brain tumor). The usual treatment for craniopharyngioma involves surgery and radiation, which helps reduce ...
Phase
Interventional
-
A Phase 3 Randomized Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician s Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse-011)
This is a Phase 3 study testing whether the study medicine sacituzumab tirumotecan ( sac-TMT, antibody-drug conjugate (ADC) targeting TROP2), given alone or with pembrolizumab (immunotherapy ...
Phase
Interventional
-
A Phase 1a/1b Open-Label Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - the ONKORAS-101 Study
This is a Phase 1 study testing whether the new medicine BBO-8520 (a KRASG12C on/off inhibitor) is a safe and effective treatment option if ...
Phase
Interventional
-
A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkin s Lymphoma
This is a multicenter, open-label Phase 1 study testing a new drug called ARV-393 in adults with advanced non-Hodgkin lymphoma (NHL). The study will look ...
Phase
Interventional
-
A Phase 3 Double-blind Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors are HER2- negative Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-positive.
This is a Phase 3 study testing whether the study medicine zolbetuximab (monoclonal antibody), together with pembrolizumab (PD-L1 inhibitors ) and chemotherapy (CAPOX or mFOLFOX6), works ...
Phase
Interventional
-
A Study to Assess the Safety of Intratumoral Diffusing Alpha Radiation Emitters with Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
This is a one-arm study testing whether the new treatment with Alpha DaRT (a medical device fitted inside the tumor that emits radiation), together with ...
Phase N/A Interventional
-
A Phase 1a/b Study Investigating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activity of BGB-58067 an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors
This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 ...Phase
Interventional
-
Expanded Access Program (EAP) for Obecabtagene-Autoleucel (Obe-Cel) Out-Of-Specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia - AUTO1-OS1
The purpose of this program is to provide access to obe-cel treatment for adult patients with ALL who have undergone leukapheresis and had obe-cel manufactured ...Phase N/A Interventional
-
A Phase 1/2 open label first-in-human dose escalation and expansion study for the evaluation of safety pharmacokinetics pharmacodynamics and anti-tumor activity of SAR445877 administered as monotherapy or in combination with other anticancer therapies in adults with advanced solid tumors
This is an open-label, multi-center study testing whether the study medicine, SAR445877, (new fusion protein combining anti-programmed cell death 1 (PD1) antibody with modified interleukin ...
Phase
Interventional
